Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC012300 | Panoply™ Human PPT1 Knockdown Stable Cell Line | Inquiry |
| CSC-SC012300 | Panoply™ Human PPT1 Over-expressing Stable Cell Line | Inquiry |
| CLOE-0223 | Human PPT1(His) HEK293 Cell Lysate | Inquiry |
| CLOE-0227 | Human PPT1(Fc) HEK293 Cell Lysate | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD12783Z | Human PPT1 adenoviral particles | Inquiry |
| LV22540L | human PPT1 (NM_001142604) lentivirus particles | Inquiry |
| LV22541L | human PPT1 (NM_000310) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH381732 | shRNA set against Rat PPT1 (NM_022502.2) | Inquiry |
| SHW001534 | shRNA set against Chicken PPT1 (NM_001030903) | Inquiry |
| SHH381724 | shRNA set against Human PPT1 (NM_000310.3) | Inquiry |
| SHH381728 | shRNA set against Mouse PPT1 (NM_008917.3) | Inquiry |
| SHR135966 | shRNA set against Rat Ppt1(NM_022502.2) | Inquiry |
| SHW018410 | shRNA set against Danio rerio PPT1 (NM_213339) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCB193747 | Rabbit PPT1 ORF clone (XM_002715190.2) | Inquiry |
| CDCH067184 | human PPT1 ORF clone (NM_001142604.1) | Inquiry |
| CDFH014979 | Human PPT1 cDNA Clone(NM_001142604.1) | Inquiry |
| CDFR011859 | Rat Ppt1 cDNA Clone(NM_022502.2) | Inquiry |
| MiUTR1R-06025 | PPT1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-03590 | PPT1 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-03591 | PPT1 miRNA 3'UTR clone | Inquiry |
| CDCB158821 | Human PPT1 ORF clone (BC008426) | Inquiry |
| CDCB163009 | Chicken PPT1 ORF Clone (NM_001030903) | Inquiry |
| CDCB179885 | Danio rerio PPT1 ORF Clone (NM_213339) | Inquiry |
| CDCH067188 | Mouse Ppt1 ORF clone (NM_008917.3) | Inquiry |
| CDCR379018 | Rat Ppt1 ORF Clone(NM_022502.2) | Inquiry |
| CDCS405569 | Human PPT1 ORF Clone (BC008426) | Inquiry |